A Study of OR502 for Advanced Solid Tumors
This study is testing a new treatment called OR502, which is an antibody that targets a protein called LILRB2. It's being studied alone and in combination with another approved cancer medicine called cemiplimab. This study is for people aged 18 and older with advanced solid tumors (cancers that form solid masses). The main goals are to understand the safety of OR502, what side effects it might cause, and how well it works against cancer. The study is currently recruiting for some parts, including those with advanced solid tumors, platinum-resistant ovarian cancer, cutaneous squamous cell carcinoma, and cutaneous melanoma.
- Study design
- This is an open-label, multi-center study, meaning you and your doctors will know which treatment you are receiving. It is a Phase 1-2 study, which typically involves a small number of participants (up to 168 planned) to first find a safe dose and then to see how well the treatment works.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your vital signs, adverse events, and serious adverse events will be monitored from screening up to 90 days after your last dose of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
At a glance
Conditions
Where it's being run
4 sites across 2 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Dose-limiting ToxicityFirst 21 days of treatment.
The incidence of DLTs during the DLT assessment period.
- Adverse Events and Serious Adverse EventsScreening to 90 days from last dose.
The nature, frequency, and severity of adverse events and serious adverse events graded by CTCAE v 5.0 as aggregated descriptive findings.
- Vital SignsScreening to 90 days from last dose.
Assessment of changes in vital sign measurements (heart rate, pulse oximetry and blood pressure) as aggregated descriptive findings.
- Recommended Dose and Regimen (mono and combination therapy)Screening to 90 days from last dose.
Determination of the recommended dose of OR502 for further development.